(Q44011735)

28 November 2017

title

Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up (English)

1 reference

Japanese encephalitis virus

28 November 2017

main subject

0 references

Japanese encephalitis

1 reference

based on heuristic

inferred from title

Japanese encephalitis vaccine

1 reference

1 reference

4

Bernd Jilma

1 reference

28 November 2017

author name string

Katrin Dubischar-Kastner

1

1 reference

28 November 2017

Astrid Kaltenboeck

2

1 reference

28 November 2017

Anton Klingler

3

1 reference

28 November 2017

Elisabeth Schuller

5

1 reference

28 November 2017

language of work or name

English

0 references

publication date

29 July 2010

1 reference

28 November 2017

1 reference

28 November 2017

volume

28

1 reference

28 November 2017

issue

39

1 reference

28 November 2017

page(s)

6463-6469

1 reference

Side-effects with Japanese encephalitis vaccine

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

Allergic mucocutaneous reactions to Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

Adverse reactions to Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

Further experience with Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

Anaphylaxis after vaccination due to hypersensitivity to gelatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

IgE sensitization to gelatin: the probable role of gelatin-containing diphtheria-tetanus-acellular pertussis (DTaP) vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

Immediate allergic reactions after vaccinations--a post-marketing surveillance review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

Two patterns of systemic immediate-type reactions to Japanese encephalitis vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

Specific IgE and IgG to gelatin in children with systemic cutaneous reactions to Japanese encephalitis vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.040

10.1016/J.VACCINE.2010.07.040

7 January 2021

Identifiers

DOI

1 reference

28 November 2017

1 reference